210 likes | 389 Views
Outline of presentation. Update of results from the randomised CALGB 9712 trial of sequential versus concurrent fludarabine and rituximab Retrospective comparison of response and survival data from CALGB 9712 (fludarabine and rituximab) and CALGB 9011 (fludarabine alone) studies. CALGB = Cancer and
E N D
1. Sequential versus concurrent fludarabine and rituximab in previously untreated chronic lymphocytic leukaemia Dr T Lin College of Medicine and Public HealthThe Ohio State University, USA